



Corrigendum

Corrigendum to “The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1 β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study”

Karina Karina ^{1,2,3,4}, **Louis Martin Christoffel**⁵, **Rita Novariani**⁵, **Imam Rosadi** ^{2,6},
Iis Rosliana², **Siti Rosidah**⁵, **Siti Sobariah**², **Novy Fatkhurohman**⁵,
Nurlaela Puspitaningrum⁵, **Yuli Hertati**⁵, **Irsyah Afini**², **Difky Ernanda**², **Tias Widyastuti**²,
A. D. Sulaeha¹, **Alfida Zakiyah**², **Noor Aini**², **Grady Krisandi**^{2,7} and **Hubert Andrew**^{2,7}

¹Klinik Hayandra, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta, Indonesia

²HayandraLab, Yayasan Hayandra Peduli, Jl. Kramat VI No. 11, Jakarta, Indonesia

³Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia

⁴Pusat Kajian Stem Cell, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia

⁵Koja Regional Public Hospital, Jl. Deli No. 4, Jakarta, Indonesia

⁶Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia

⁷Universitas Indonesia, Jl. Salemba Raya No. 6, Jakarta, Indonesia

Correspondence should be addressed to Karina Karina; karina@hayandra.com

Received 1 December 2022; Accepted 1 December 2022; Published 3 February 2023

Copyright © 2023 Karina Karina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article “The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1 β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study” [1], the authors would like to update the Methods section as follows.

2. Methods

This interventional preliminary study recruited 12 patients of both sexes between the age of 18–65 years as interim data of Phase II clinical trials. The study protocol was ethically approved by the Health Research Ethics Committee, University of Indonesia, and Cipto Mangunkusumo Hospital (HREC-FMUI/CMH) and is registered on ClinicalTrials.gov (NCT04715360).

References

- [1] K. Karina, L. M. Christoffel, R. Novariani et al., “The Effect of Intravenous Autologous Activated Platelet-Rich Plasma

Therapy on “Profibrotic Cytokine” IL-1 β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study,” *Scientifica*, vol. 2021, Article ID 9427978, 7 pages, 2021.